A statement Spectral should release the name of the “Confirmed Clinical Partner” or a statement as to why they assert that the withholding of the partner's name is more responsible than fair and timely disclosure to investors.
Four months have passed since the announcement. If the withholding of this material fact is inappropriate it opens the company to real liability.
I imagine we will hear nothing until after the close of financing next week, but you could also see how that could compound potential issues.
Confirmed Clinical Partner- AGM Presentation (slide 15)
https://spectraldx.com/wp-content/uploads/2022/06/spectral-agm-2022-presentation.pdf